XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Information
 6 Months Ended
Dec. 31, 2022
Segment Information  
Segment Information

16. Segment Information

 

Segment and geographical information is reported as follows:

  

Six Months Ended December 31, 2022

 

Benchtop Laboratory Equipment

 

 

Bioprocessing Systems

 

 

Corporate

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

$4,608,900

 

 

$628,900

 

 

$-

 

 

$5,237,800

 

Foreign Sales

 

 

1,322,500

 

 

 

478,200

 

 

 

-

 

 

 

1,800,700

 

Income (Loss) From Operations

 

 

203,500

 

 

 

(3,483,200)

 

 

(902,300)

 

 

(4,137,000)

Assets

 

 

8,622,500

 

 

 

5,174,600

 

 

 

4,272,100

 

 

 

18,069,200

 

Long-Lived Asset Expenditures

 

 

34,300

 

 

 

220,200

 

 

 

-

 

 

 

254,500

 

Depreciation and Amortization

 

 

50,100

 

 

 

330,700

 

 

 

-

 

 

 

380,800

 

Six Months Ended December 31, 2021 (Unaudited)

 

Benchtop Laboratory Equipment

 

 

Bioprocessing Systems

 

 

Corporate

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

$5,031,100

 

 

$727,500

 

 

$-

 

 

$5,758,600

 

Foreign Sales

 

 

2,031,100

 

 

 

521,500

 

 

 

-

 

 

 

2,552,600

 

Income (Loss) From Operations

 

 

851,700

 

 

 

(3,712,700)

 

 

(508,200)

 

 

(3,369,200)

Assets

 

 

9,715,400

 

 

 

10,064,500

 

 

 

9,072,600

 

 

 

28,852,500

 

Long-Lived Asset Expenditures

 

 

66,600

 

 

 

163,300

 

 

 

-

 

 

 

229,900

 

Depreciation and Amortization

 

 

46,600

 

 

 

280,700

 

 

 

-

 

 

 

327,300

 

   

Year Ended June 30, 2022 (As Restated)

 

Benchtop Laboratory Equipment

 

 

Bioprocessing Systems

 

 

Corporate

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

$9,981,100

 

 

$1,419,400

 

 

$-

 

 

$11,400,500

 

Foreign Sales

 

 

3,702,400

 

 

 

1,101,400

 

 

 

-

 

 

 

4,803,800

 

Income (Loss) From Operations

 

 

1,475,800

 

 

 

(11,369,500)

 

 

(1,650,400)

 

 

(11,544,100)

Assets

 

 

9,538,600

 

 

 

5,077,500

 

 

 

6,391,800

 

 

 

21,007,900

 

Long-Lived Asset Expenditures

 

 

92,500

 

 

 

732,100

 

 

 

-

 

 

 

824,600

 

Depreciation and Amortization

 

 

96,300

 

 

 

591,900

 

 

 

-

 

 

 

688,200

 

 

Year Ended June 30, 2021

 

Benchtop Laboratory Equipment

 

 

Bioprocessing Systems

 

 

Corporate

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

$9,043,600

 

 

$731,600

 

 

$-

 

 

$9,775,200

 

Foreign Sales

 

 

3,483,700

 

 

 

684,600

 

 

 

-

 

 

 

4,168,300

 

Income (Loss) From Operations

 

 

1,461,300

 

 

 

(4,828,600)

 

 

(1,341,400)

 

 

(4,708,700)

Assets

 

 

14,783,000

 

 

 

8,735,100

 

 

 

5,488,300

 

 

 

29,006,400

 

Long-Lived Asset Expenditures

 

 

60,500

 

 

 

196,900

 

 

 

-

 

 

 

257,400

 

Depreciation and Amortization

 

 

103,100

 

 

 

148,400

 

 

 

-

 

 

 

251,500

 

 

Geographical Information

 

 

 

Six Months Ended

 

 

 

December 31, 2022

 

 

December 31, 2021 (unaudited)

 

 

 

Revenue (a)

 

 

Long-Lived Assets

 

 

Revenue (a)

 

 

Long-Lived Assets

 

United States

 

$3,437,000

 

 

$1,710,000

 

 

$3,206,000

 

 

$5,181,300

 

All Other Foreign Countries

 

 

1,454,700

 

 

 

-

 

 

 

2,276,100

 

 

 

-

 

Germany

 

 

346,100

 

 

 

885,000

 

 

 

276,500

 

 

 

138,000

 

Total

 

$5,237,800

 

 

$2,595,000

 

 

$5,758,600

 

 

$5,319,300

 

 

(a) Revenues are attributed to countries based on location of customer

 

For the six months ended December 31, 2022, one customer accounted for approximately $545,300 revenue from the Benchtop Laboratory Equipment Segment, of which the revenue is 10% or more of the Company’s total revenue. For the six months ended December 31, 2021 (unaudited) and for the year ended June 30, 2022 and 2021, respectively, there are no individual customer accounted for approximately 10% or more of the Company’s total revenue.

A reconciliation of the Company's consolidated segment income/loss from operations to consolidated income (loss) from operations before discontinued operations and income taxes for the six months ended December 31, 2022 and 2021 (unaudited), respectively and for the year ended June 30, 2022 and 2021, respectively are as follows:

 

Six Months ended December 31, 2022

 

Benchtop Laboratory Equipment

 

 

Bioprocessing Systems

 

 

Corporate

 

 

Consolidated

 

Income (Loss) from Operations

 

$203,500

 

 

$(3,438,200)

 

$(902,300)

 

$(4,137,000)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other (expense) income, net

 

 

(28,200)

 

 

3,600

 

 

88,500

 

 

 

63,900

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (Loss) from operations before discontinued operations and income taxes

 

$175,300

 

 

$(3,434,600)

 

$(813,800)

 

$(4,073,100)

 

Six Months ended December 31, 2021 (unaudited)

 

Benchtop Laboratory Equipment

 

 

Bioprocessing Systems

 

 

Corporate

 

 

Consolidated

 

Income (Loss) from Operations

 

$851,700

 

 

$(3,712,700)

 

$(508,200)

 

$(3,369,200)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other (expense) income, net

 

 

415,500

 

 

 

52,500

 

 

 

47,600

 

 

 

515,600

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (Loss) from operations before discontinued operations and income taxes

 

$1,267,200

 

 

$(3,660,200)

 

$(460,600)

 

$(2,853,600)

 

Year ended June 30, 2022 (As Restated)

 

Benchtop Laboratory Equipment

 

 

Bioprocessing Systems

 

 

Corporate

 

 

Consolidated

 

Income (Loss) from Operations

 

$1,475,800

 

 

$(11,369,500)

 

$(1,650,400)

 

$(11,544,100)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other (expense) income, net

 

 

194,000

 

 

 

(3,100)

 

 

71,500

 

 

 

262,400

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (Loss) from operations before discontinued operations and income taxes

 

$1,669,800

 

 

$(11,372,600)

 

$(1,578,900)

 

$(11,281,700)

     

Year ended June 30, 2021

 

Benchtop Laboratory Equipment

 

 

Bioprocessing Systems

 

 

Corporate

 

 

Consolidated

 

Income (Loss) from Operations

 

$1,461,300

 

 

$(4,828,600)

 

$(1,341,500)

 

$(4,708,800)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other (expense) income, net

 

 

571,000

 

 

 

600

 

 

 

82,200

 

 

 

653,800

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (Loss) from operations before discontinued operations and income taxes

 

$2,032,300

 

 

$(4,828,000)

 

$(1,259,300)

 

$(4,055,000)